Anna E Mason1, Ethan S Sen1, Agnieszka Bierzynska1, Elizabeth Colby1, Maryam Afzal1, Guillaume Dorval2, Ania B Koziell3, Maggie Williams4, Olivia Boyer2, Gavin I Welsh1, Moin A Saleem5. 1. Bristol Renal, Translational Health Sciences, Bristol Medical School, University of Bristol, Bristol, United Kingdom. 2. Department of Pediatric Nephrology, Reference Center for Hereditary Kidney Diseases, Necker Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France. 3. Division of Transplantation Immunology and Mucosal Biology, Department of Experimental Immunobiology, Faculty of Life Sciences and Medicine, King's College London, London, United Kingdom. 4. Bristol Genetics Laboratory, Pathology Sciences, Southmead Hospital, Bristol, United Kingdom. 5. Bristol Renal, Translational Health Sciences, Bristol Medical School, University of Bristol, Bristol, United Kingdom M.saleem@bristol.ac.uk.
Abstract
BACKGROUND AND OBJECTIVES: Intensified immunosuppression in steroid-resistant nephrotic syndrome is broadly applied, with disparate outcomes. This review of patients from the United Kingdom National Study of Nephrotic Syndrome cohort aimed to improve disease stratification by determining, in comprehensively genetically screened patients with steroid-resistant nephrotic syndrome, if there is an association between response to initial intensified immunosuppression and disease progression and/or post-transplant recurrence. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Pediatric patients with steroid-resistant nephrotic syndrome were recruited via the UK National Registry of Rare Kidney Diseases. All patients were whole-genome sequenced, whole-exome sequenced, or steroid-resistant nephrotic syndrome gene-panel sequenced. Complete response or partial response within 6 months of starting intensified immunosuppression was ascertained using laboratory data. Response to intensified immunosuppression and outcomes were analyzed according to genetic testing results, pattern of steroid resistance, and first biopsy findings. RESULTS: Of 271 patients, 178 (92 males, median onset age 4.7 years) received intensified immunosuppression with response available. A total of 4% of patients with monogenic disease showed complete response, compared with 25% of genetic-testing-negative patients (P=0.02). None of the former recurred post-transplantation. In genetic-testing-negative patients, 97% with complete response to first intensified immunosuppression did not progress, whereas 44% of nonresponders developed kidney failure with 73% recurrence post-transplant. Secondary steroid resistance had a higher complete response rate than primary/presumed resistance (43% versus 23%; P=0.001). The highest complete response rate in secondary steroid resistance was to rituximab (64%). Biopsy results showed no correlation with intensified immunosuppression response or outcome. CONCLUSIONS: Patients with monogenic steroid-resistant nephrotic syndrome had a poor therapeutic response and no post-transplant recurrence. In genetic-testing-negative patients, there was an association between response to first intensified immunosuppression and long-term outcome. Patients with complete response rarely progressed to kidney failure, whereas nonresponders had poor kidney survival and a high post-transplant recurrence rate. Patients with secondary steroid resistance were more likely to respond, particularly to rituximab.
BACKGROUND AND OBJECTIVES: Intensified immunosuppression in steroid-resistant nephrotic syndrome is broadly applied, with disparate outcomes. This review of patients from the United Kingdom National Study of Nephrotic Syndrome cohort aimed to improve disease stratification by determining, in comprehensively genetically screened patients with steroid-resistant nephrotic syndrome, if there is an association between response to initial intensified immunosuppression and disease progression and/or post-transplant recurrence. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Pediatric patients with steroid-resistant nephrotic syndrome were recruited via the UK National Registry of Rare Kidney Diseases. All patients were whole-genome sequenced, whole-exome sequenced, or steroid-resistant nephrotic syndrome gene-panel sequenced. Complete response or partial response within 6 months of starting intensified immunosuppression was ascertained using laboratory data. Response to intensified immunosuppression and outcomes were analyzed according to genetic testing results, pattern of steroid resistance, and first biopsy findings. RESULTS: Of 271 patients, 178 (92 males, median onset age 4.7 years) received intensified immunosuppression with response available. A total of 4% of patients with monogenic disease showed complete response, compared with 25% of genetic-testing-negative patients (P=0.02). None of the former recurred post-transplantation. In genetic-testing-negative patients, 97% with complete response to first intensified immunosuppression did not progress, whereas 44% of nonresponders developed kidney failure with 73% recurrence post-transplant. Secondary steroid resistance had a higher complete response rate than primary/presumed resistance (43% versus 23%; P=0.001). The highest complete response rate in secondary steroid resistance was to rituximab (64%). Biopsy results showed no correlation with intensified immunosuppression response or outcome. CONCLUSIONS: Patients with monogenic steroid-resistant nephrotic syndrome had a poor therapeutic response and no post-transplant recurrence. In genetic-testing-negative patients, there was an association between response to first intensified immunosuppression and long-term outcome. Patients with complete response rarely progressed to kidney failure, whereas nonresponders had poor kidney survival and a high post-transplant recurrence rate. Patients with secondary steroid resistance were more likely to respond, particularly to rituximab.
Authors: D C Cattran; G B Appel; L A Hebert; L G Hunsicker; M A Pohl; W E Hoy; D R Maxwell; C L Kunis Journal: Kidney Int Date: 1999-12 Impact factor: 10.612
Authors: Bernward G Hinkes; Bettina Mucha; Christopher N Vlangos; Rasheed Gbadegesin; Jinhong Liu; Katrin Hasselbacher; Daniela Hangan; Fatih Ozaltin; Martin Zenker; Friedhelm Hildebrandt Journal: Pediatrics Date: 2007-03-19 Impact factor: 7.124
Authors: Agnieszka Bierzynska; Katrina Soderquest; Philip Dean; Elizabeth Colby; Ruth Rollason; Caroline Jones; Carol D Inward; Hugh J McCarthy; Michael A Simpson; Graham M Lord; Maggie Williams; Gavin I Welsh; Ania B Koziell; Moin A Saleem Journal: J Am Soc Nephrol Date: 2016-12-08 Impact factor: 10.121
Authors: Alberto Magnasco; Pietro Ravani; Alberto Edefonti; Luisa Murer; Luciana Ghio; Mirco Belingheri; Elisa Benetti; Corrado Murtas; Giovanni Messina; Laura Massella; Maria Gabriella Porcellini; Michela Montagna; Mario Regazzi; Francesco Scolari; Gian Marco Ghiggeri Journal: J Am Soc Nephrol Date: 2012-05-10 Impact factor: 10.121
Authors: Ethan S Sen; Philip Dean; Laura Yarram-Smith; Agnieszka Bierzynska; Geoff Woodward; Chris Buxton; Gemma Dennis; Gavin I Welsh; Maggie Williams; Moin A Saleem Journal: J Med Genet Date: 2017-08-05 Impact factor: 6.318